BRIEF-4SC AG gives headline results from Phase II trial of resminostat

* 4SC provides headline results from Yakult Honsha's Phase II trial of resminostat in

combination with sorafenib as first line therapy in liver cancer

Source text for Eikon:

Further company coverage:

(Gdynia Newsroom)

Read more